David D’Amico, PhD

Davide is a research scientist in the field of metabolism and aging. He was previously a post-doc at the Auwerx Laboratory of Integrative Systems Physiology at the École Polytechnique Fédérale de Lausanne (EPFL), where he investigated the role of mitochondrial function in health, disease, and the aging process.

Davide is currently working as a scientific project manager at Amazentis, where he is investigating naturally derived bioactive that could reverse age-related muscle decline by modulating mitochondrial function.

Amazentis’ lead bioactive is urolithin A, which has been shown to induce mitophagy in model organisms. Amazentis recently published the first human clinical trial results on urolithin A, demonstrating that regular oral administration in healthy elderly subjects was safe and effective in improving mitochondrial health, by upregulating mitochondrial gene expression in skeletal muscle.